Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 10 art units • 14 examiners • 0 of 15 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Intellia Therapeutics Inc. has 15 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 14 distinct examiners across 10 distinct art units, indicating broad examiner dispersion and multiple technical examination settings.
HASAN, KHALEDA B is the busiest examiner, with 2 pending matters. The assignment is limited relative to the portfolio total, so counsel should combine targeted examiner review with centralized tracking of claim positions, deadlines, and art-unit developments.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §103 only | 3 (20%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 2 (13%) |
| Multi-statute (no §101) | 7 (47%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASAN, KHALEDA B | 2 | 59.3% | +49.0% |
| FAN, WEIHUA | 1 | 83.3% | +12.7% |
| TATGE, LEXUS MARC | 1 | 25.0% | +100.0% |
| ZAHORIK, AMANDA MARY | 1 | 58.3% | +49.3% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 74.5% | +36.3% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 20.0% | +37.5% |
| SMALL, KATHERINE R | 1 | 69.4% | +29.6% |
| REGA, KYLE THOMAS | 1 | 63.0% | +41.7% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17836265 | Modified Guide RNAs for Gene Editing | ARIETI, RUTH SOPHIA | 30d overdue |
| 18700487 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | TATGE, LEXUS MARC | — |
| 18572155 | METHODS FOR IN VIVO EDITING OF A LIVER GENE | ZAHORIK, AMANDA MARY | — |
| 18339665 | Compositions and Methods for Reducing HLA-A in a Cell | SPENCER, ANDREA LYNNE MORRIS | — |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | SMALL, KATHERINE R | — |
| 18332335 | Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination | REGA, KYLE THOMAS | — |
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | KIM, TAEYOON | — |
| 16651911 | FORMULATIONS | BURKHART, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18050333 | Methods of in Vitro Cell Delivery | ZHU, JIANJIAN | 6d |
| 19630254 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | HASAN, KHALEDA B | — |
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | — |
| 18700487 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | TATGE, LEXUS MARC | — |
| 18572155 | METHODS FOR IN VIVO EDITING OF A LIVER GENE | ZAHORIK, AMANDA MARY | — |
| 18287227 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | HEASLEY, MEGHAN CHRISTINE | — |
| 18339665 | Compositions and Methods for Reducing HLA-A in a Cell | SPENCER, ANDREA LYNNE MORRIS | — |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | SMALL, KATHERINE R | — |
| Art Unit | Apps |
|---|---|
| 1636 | 4 |
| 1631 | 3 |
| 1663 | 1 |
| 1637 | 1 |
| 1626 | 1 |
| 1633 | 1 |
| 1656 | 1 |
| 1635 | 1 |
| 1634 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19630254 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | HASAN, KHALEDA B | 1636 | §103DP | Non-Final OA | — | Pending | Mar 26, 2026 |
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | 1663 | DP | Non-Final OA | — | Pending | Jul 22, 2025 |
| 18700487 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | TATGE, LEXUS MARC | 1637 | §101§103§112DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18572155 | METHODS FOR IN VIVO EDITING OF A LIVER GENE | ZAHORIK, AMANDA MARY | 1636 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18287227 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | HEASLEY, MEGHAN CHRISTINE | 1626 | §103 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18339665 | Compositions and Methods for Reducing HLA-A in a Cell | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | SMALL, KATHERINE R | 1633 | §102§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18332335 | Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination | REGA, KYLE THOMAS | 1636 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | KIM, TAEYOON | 1631 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18050333 | Methods of in Vitro Cell Delivery | ZHU, JIANJIAN | 1631 | §103Other | Final Rejection | 6d | Pending | Oct 27, 2022 |
| 17965366 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | — | Pending | Oct 13, 2022 |
| 17836265 | Modified Guide RNAs for Gene Editing | ARIETI, RUTH SOPHIA | 1635 | §102§103§112Other | Final Rejection | 30d overdue | Pending | Jun 09, 2022 |
| 17735929 | Methods and Compositions for Directed Genome Editing | HASAN, KHALEDA B | 1636 | §103§112DP | Non-Final OA | — | Pending | May 03, 2022 |
| 17111769 | Modified Guide RNAs for Gene Editing | PENNINGTON, KATIE LEIGH | 1634 | Other | Non-Final OA | 17d overdue | Pending | Dec 04, 2020 |
| 16651911 | FORMULATIONS | BURKHART, MICHAEL D | 1638 | §102§103 | Final Rejection | — | Pending | Mar 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIntellia Therapeutics Inc. has 15 pending office actions as of October 2026, spread across 10 art units and 14 examiners.
Khaleda B Hasan has the most, with 2 of Intellia Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
